Crescent Biopharma, Inc. (CBIO) — Working Capital to Net Assets Ratio
Crescent Biopharma, Inc. (CBIO) has a Working Capital to Net Assets ratio of 98.3% as of June 2026. Working capital of $160.47 Million (current assets of $179.01 Million minus current liabilities of $18.54 Million) is measured against net assets of $163.25 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Crescent Biopharma, Inc. (CBIO) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Crescent Biopharma, Inc. Working Capital to Net Assets (2011–2025)
This chart shows how Crescent Biopharma, Inc.'s Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 98.3%, reflecting working capital of $160.47 Million against net assets of $163.25 Million USD. For the complete balance sheet picture, see CBIO total asset value.
Annual Working Capital to Net Assets for Crescent Biopharma, Inc. (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Crescent Biopharma, Inc. from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check asset resilience ratio of Crescent Biopharma, Inc. to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 98.8% | $200.58 Million | $203.01 Million | $236.66 Million | $36.07 Million | ▲ +261.5 pp |
| 2024 | -162.7% | $25.19 Million | $-15.48 Million | $34.80 Million | $9.61 Million | ▼ -258.9 pp |
| 2023 | 96.2% | $36.96 Million | $38.41 Million | $43.79 Million | $6.84 Million | ▼ -1.2 pp |
| 2022 | 97.4% | $41.83 Million | $42.93 Million | $50.71 Million | $8.88 Million | ▲ +0.7 pp |
| 2021 | 96.8% | $78.96 Million | $81.60 Million | $90.79 Million | $11.82 Million | ▼ -1.4 pp |
| 2020 | 98.1% | $125.84 Million | $128.22 Million | $138.27 Million | $12.43 Million | ▼ -0.2 pp |
| 2019 | 98.3% | $151.58 Million | $154.20 Million | $162.53 Million | $10.95 Million | ▼ -0.7 pp |
| 2018 | 99.0% | $203.51 Million | $205.46 Million | $212.27 Million | $8.76 Million | ▼ -0.4 pp |
| 2017 | 99.5% | $119.04 Million | $119.70 Million | $127.22 Million | $8.17 Million | ▲ +2.6 pp |
| 2016 | 96.8% | $34.19 Million | $35.30 Million | $40.52 Million | $6.33 Million | ▼ -0.7 pp |
| 2015 | 97.6% | $39.50 Million | $40.47 Million | $47.24 Million | $7.75 Million | ▼ -0.1 pp |
| 2014 | 97.7% | $49.65 Million | $50.80 Million | $56.12 Million | $6.46 Million | ▲ +8.2 pp |
| 2013 | 89.6% | $2.60 Million | $2.91 Million | $4.88 Million | $2.28 Million | ▼ -8.4 pp |
| 2012 | 98.0% | $12.28 Million | $12.53 Million | $17.97 Million | $5.69 Million | ▼ -43.4 pp |
| 2011 | 141.4% | $11.95 Million | $8.46 Million | $28.37 Million | $16.41 Million | — |